Journals / Nöropsikiyatri Arşivi / 2016 / Cilt: 53 - Sayı: 3

Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?

Majör Depresif Epizotun Tedavisinde Erken Yanıt ile Nihai Yanıt Öngörülebilir mi?

Pages
245–252
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Close monitoring of the response from the first week of treatment may thus help the clinician to predict the subsequent response.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: New evidence suggests that the efficacy of antidepressants occurs within the first weeks of treatment and this early response predicts the later response.
📊
Key Findings & Data:The purpose of the present study was to investigate if the partial response in the first week predicts the response at the end of treatment in patients with major depressive disorder who are treated with either antidepressant medication or electroconvulsive therapy.Methods: Inpatients from Dokuz Eylül University Hospital with a major depressive episode, treated with antidepressant medication (n=52) or electroconvulsive therapy (ECT) (n=48), were recruited for the study.
💡
Conclusion & Impact:Close monitoring of the response from the first week of treatment may thus help the clinician to predict the subsequent response.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: New evidence suggests that the efficacy of antidepressants occurs within the first weeks of treatment and this early response predicts the later response. The purpose of the present study was to investigate if the partial response in the first week predicts the response at the end of treatment in patients with major depressive disorder who are treated with either antidepressant medication or electroconvulsive therapy.Methods: Inpatients from Dokuz Eylül University Hospital with a major depressive episode, treated with antidepressant medication (n=52) or electroconvulsive therapy (ECT) (n=48), were recruited for the study. The data were retrospectively collected to decide whether a 25% decrease in the Hamilton Depression Rating Scale (HDRS) score at the first week of treatment predicts a 50% decrease at the third week using validity analysis. In addition, the effects of socio-demographic and clinical variables on the treatment response were assessed Results: A 25% decrease in the HDRS score in the first week of treatment predicted a 50% decrease in the HDRS score in the third week with a 78.3% positive predictive value, 62.1% negative predictive value, 62.1% sensitivity, and 78.3% specificity for antidepressant medications and an 88% positive predictive value, 52.2% negative predictive value, 66.7% sensitivity, and 80% specificity for ECT. The number of previous hospitalizations, comorbid medical illnesses, number of depressive episodes, duration of illness, and duration of the current episode were related to the treatment response. Conclusion: Treatment response in the first week predicted the response in the third week with a high specificity and a high positive predictive value. Close monitoring of the response from the first week of treatment may thus help the clinician to predict the subsequent response.

Özet

Amaç: Yeni kanıtlar antidepresan ilaçların etkinliğinin ilk haftalarda ortaya çıktığı ve bu erken yanıtın nihai tedavi yanıtı için öngörücü olduğuna işaret etmektedir. Bu çalışmanın amacı majör depresif bozukluk tanılı hastalarda uygulanan antidepresan tedavi ve elektrokonvülzif terapinin (EKT) birinci haftada gözlenen kısmi yanıtın tedavi sonunda gözlenen yanıt için yordayıcılığını araştırmaktır. Yöntem: Çalışmaya Dokuz Eylül Üniversite Hastanesi Psikiyatri Servisinde majör depresif epizot tanısı ile yatarak izlenen ve antidepresan ilaç (n=52) ya da EKT (n=48) uygulanan hastalar alınmıştır. Hastaların verileri geriye dönük olarak taranarak birinci haftada Hamilton Depresyon Ölçeği (HDÖ) puanında gözlenen %25 düşüşün üçüncü haftada %50 düşüşü yordayıcılığı geçerlilik analizi ile araştırılmıştır. Ayrıca sosyo-demografik ve klinik değişkenlerin yanıt üzerindeki etkileri incelenmiştir. Bulgular: Birinci haftada HDÖ puanındaki %25 düşüşün, üçüncü haftada HDÖ puanındaki %50 düşüşü antidepresan ilaçlar için %78,3 pozitif öngörücü değer, %62,1 negatif öngörücü değer, %62,1 duyarlılık ve %78,3 özgüllük; EKT için %88 pozitif öngörücü değer, %52,2 negatif öngörücü değer, %66,7 duyarlılık ve %80 özgüllük ile yordadığı bulunmuştur. Önceki hastaneye yatış sayısı, komorbid tıbbi hastalık varlığı, toplam epizot sayısı, hastalık süresi, şimdiki epizotun süresinin tedaviye yanıt ile ilişkili olduğu saptanmıştır. Sonuç: Birinci haftada gözlenen yanıt üçüncü hafta gözlenen yanıtı yüksek bir özgüllük ve pozitif öngörücü değer ile yordamaktadır. Tedavi yanıtının birinci haftadan itibaren yakından izlenmesi daha sonraki yanıtın öngörülmesini sağlayabilir.

🔖

Cite This Article

ÇİFTÇİ, A., ULAŞ, H., TOPUZOĞLU, A., TUNCA, Z. (2016). Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?. Nöropsikiyatri Arşivi, Cilt: 53 - Sayı: 3, 245–252. https://ajindex.com/articles/292357

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011; 7(Suppl 1):3-7.
  2. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford HA. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013; 43:471-481. [CrossRef] Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T, Whiteford HA. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013; 10:e1001547. [CrossRef] Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60:1439-1445. [CrossRef] Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Pa- rikh SV, PattenB, RavindranAV; Canadian Network for Mood and AnxietyTre- atments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of majordepressive disor- der in adults. III. Pharmacotherapy. J Affect Disord 2009; 117(Suppl 1):26-43. [CrossRef] Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, De- Battista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychi- atry 1999; 60:142-156. [CrossRef] American Psychiatric Association. Practice Guideline for the Treatment of the Patients with Major Depressive Disorder. Available from: http://psychiatryon- line.org/guidelines, Erişim tarihi: 17.12.2014.
  3. Nierenberg AA, Faraburgh AH, Alpert JE, Gordon J, Worthington JJ, Rosen- baum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423-1428. [CrossRef] Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and me- ta-analysis. Arch Gen Psychiatry 2006; 63:1217-1223. [CrossRef] Stassen HH, Delini-Stula A, Angst J. Time course of improvement under an- tidepressant treatment: a survival-analytical approach. Eur Neuropsychophar- macol 1993; 3:127-135. [CrossRef] Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepres- sants a